Acneaway
Acneaway Cream
Anti-infective/Corticosteroid combinations, Skin
Cream (NRN:04-2733): Econazole nitrate 10 mg, Triamcinolone acetonide 1 mg, Gentamicin sulfate 1 mg in a cream base.
Pack size: 30 g tube.
Acneaway cream contains dematomycosis agent i.e, antifungal, antibacterial and corticosteroid. It is well absorbed on topical application.
Econazole nitrate is a broad-spectrum antifungal agent with activity against many gram-positive bacteria.
Triamcinolone acetonide is a potent corticosteroid with anti-inflammatory, antipruritic and antiallergic activity.
Gentamicin sulphate is a wide-spectrum antibiotic, which provides highly effective treatment in primary and secondary bacterial infections of the skin.
For the topical treatment of inflammatory dermatomycoses and inflammatory skin conditions complicated by bacterial or fungal skin infection:
Allergic inflammatory dermatoses (eczema, dermatitis, diaper dermatitis, intertrigo, etc)
Trychophytosis: tinea pedis, tinea corporis, tinea faciei, tinea capitis, tinea cruris, tinea sycosis.
Tinea versicolor
Skin candidiasis
Bacteria skin infections caused by susceptible strains to gentamicin.
Hypersensitivity to any of the component of formulation
Patients with tuberculosis cutis, herpes simplex, varicella, herpes zoster, vaccinia and syphilis.
Eczematous otitis extema with perforated eardrum.
Ulcer (Behcet's disease), burn (exceed 2o)
Patients who have previously exhibited hypersensitivity to aminoglycoside antibiotic (such as Streptomycin, Neomycin, Kanamycin and Gentamicin) and Bacitracin.
Long-term continuous therapy, particularly occlusive dressings, should be avoided since it may cause side effects similar to systemic administration of corticosteroid.
Avoid long-term therapy: the overgrowth of non-susceptible organisms, including fungi, occasionally occurs with the use of topical antibiotic. If this occurs, or if irritation, sensitization, or super infection develops, treatment should be discontinued and appropriate therapy instituted.
If the symptom aren't being improved or are aggravated, discontinue the therapy.
If the symptom is improved, change the drug to other non-steroidal drug as soon as possible.
Safe and well tolerated. Rarely, some patients may show mild to moderate irritation (erythema and pruritus) that do not usually require discontinuation of treatment.
Other dermal symptoms: Long-term therapy may cause steroidal acne, steroidal skin (skin atropy, telangiectasis) and changes of the skin such as thinning, purpura, hirsutism and hypopigmentation. Such symptoms may occur slowly, decrease the dosage of this drug and change to non-steroidal drugs.
HPA axis dysfunction: Long-term therapy or occlusive dressings may cause hypothalamus pituitary-adrenal (HPA) axis suppression.
Apply to the affected area once to several times daily as directed by the physician.
Store in a cool place. Do not freeze. Keep the tube tightly closed after use.
Keep out of the reach of children.
Elder Pharmaceuticals Ltd, D-220, TTC Industrial Area, Navi Mumbai – 400 706, India.